A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice

Viral Immunology

Volumn 23, Issue 2, 2010, Pages 201-210

  Delaney, Kristen N ^a   Phipps, James P ^a   Johnson, John B ^a   Mizel, Steven B ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLAGELLIN; HYBRID PROTEIN; RECOMBINANT FLAGELLIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; NONHUMAN; POXVIRUS; VACCINIA; VACCINIA VIRUS; VIRUS IMMUNITY; VIRUS NEUTRALIZATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; COMPLEMENT SYSTEM PROTEINS; FEMALE; FLAGELLIN; HELA CELLS; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; SMALLPOX VACCINE; VACCINES, SYNTHETIC; VACCINIA; VACCINIA VIRUS;

BACTERIA (MICROORGANISMS); MUS; POXVIRIDAE; VACCINIA VIRUS;

EID: 77953948201     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2009.0107     Document Type: Article

References (45)

1. Applequist SE, Rollman E, Wareing MD, Liden M, Rozell B, Hinkula J, and Ljunggren HG: Activation of innate immunity, inflammation, and potentiation of DNA vaccination through mammalian expression of the TLR5 agonist flagellin. J Immunol 2005;175:3882-3891.
2. Bachmann M, Horn K, Poleganov A, Paulukat J, Nold J, Pfeilschifter J, and Muhl H: Interleukin-18 secretion and Th1-like cytokine responses in human peripheral blood mononuclear cells under the influence of the toll-like receptor-5 ligand flagellin. Cell Microbiol 2006;8:289-300.
3. Bates JT, Honko AN, Graff AH, Kock N, and Mizel SB: Mucosal adjuvant activity of flagellin in aged mice. Mech Ageing Dev 2008;129:271-281.
4. Bates JT, Uematsu S, Akira S, and Mizel SB: Direct stimulation of tlr5+=+ CD11c+ cells is necessary for the adjuvant activity of flagellin. J Immunol 2009;182:7539-7547.
5. Ben-Yedidia T, Abel L, Arnon R, and Globerson A: Efficacy of anti-influenza peptide vaccine in aged mice. Mech Ageing Dev 1998;104:11-23.
6. Ben-Yedidia T, and Arnon R: Effect of pre-existing carrier immunity on the efficacy of synthetic influenza virus. Immunol Lett 1998;64:9-15.
7. Ben-Yedidia T, Marcus H, Reisner Y, and Arnon R: Intranasal administration of peptide vaccine protects human= mouse radiation chimera from influenza infection. Int Immunol 1999;11:1043-1051.
8. Ben-Yedidia T, Tarrab-Hazdai R, Schechtman D, and Arnon R: Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Infect Immun 1999;67:4360-4366.
9. Benhnia MR, McCausland MM, Moyron J, et al.: Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J Virol 2009; 83:1201-1215.
10. Berhanu A, Wilson RL, Kirkwood-Watts DL, et al.: Vaccination of BALB=c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge. J Virol 2008;82:3517-3529.
11. Cuadros C, Lopez-Hernandez FJ, Dominguez AL, Mc-Clelland M, and Lustgarten J: Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun 2004;72:2810-2816.
12. Didierlaurent A, Ferrero I, Otten LA, et al.: Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J Immunol 2004;172:6922-6930.
13. Doms RW, Blumenthal R, and Moss B: Fusion of intra-and extracellular forms of vaccinia virus with the cell membrane. J Virol 1990;64:4884-4892.
14. Earl PL, Americo JL, and Moss B: Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein. J Virol 2003;77:10684-10688.
15. Edgehill-Smith Y, Golding H, Manischewitz J, et al.: Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nature Med 2005; 11:740-747.
16. Fang M, Cheng H, Dai Z, Bu Z, and Sigal LJ: Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host. Virology 2006;345: 231-243.
17. Fogg C, Americo JL, Lustig S, et al.: Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 2007;25:2787-2799.
18. Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, and Moss B: Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 2004; 78:10230-10237.
19. Frey SE, Newman FK, Yan L, and Belshe RB: Responses to smallpox vaccine in persons immunized in the distant past. JAMA 2003;289:3295-3299.
20. Harris TN, and Harris S: Effect of anti-mouse IgG1 on some complement-requiring alloantibodies of the mouse. J Immunol 1972;109:1096-1108.
21. Hayashi F, Smith KD, Ozinsky A, et al.: The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature 2001;410:1099-1103.
22. Heraud JM, Edgehill-Smith Y, Ayala V, et al.: Subunit recombinant vaccine protects against monkeypox. J Immunol 2006;177:2552-2564.
23. Honko AN, and Mizel SB: Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect Immun 2004;72:6676-6679.
24. Honko AN, Sriranganathan N, Lees CJ, and Mizel SB: Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect Immun 2006;74:1113-1120.
25. Hooper JW, Custer DM, Schmaljohn CS, and Schmaljohn AL: DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 2000;266:329-339.
26. Hooper JW, Custer DM, and Thompson E: Four-genecombination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology 2003;306:181-195.
27. Hooper JW, Thompson E, Wilhelmsen C, et al.: Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J Virol 2004;78:4433-4443.
28. Huleatt JW, Jacobs AR, Tang J, et al.: Vaccination with recombinant fusion proteins incorporating toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 2007;25:763-775.
29. Huleatt JW, Nakaar V, Desai P, et al.: Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008;26:201-214.
30. Jeon SH, Ben-Yedidia T, and Arnon R: Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 2002;20:2772-2780.
31. Kamboj M, and Sepkowitz K: Risk of transmission associated with live attenuated vaccines given to healthy persons caring for or residing with an immunocompromised patient. Infect Control Hosp 2007;28:702-707.
32. Lee SE, Kim SY, Jeong BC, et al.: A bacterial flagellin Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006;74:694-702.
33. Levi R, and Arnon R: Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 1996;14:85-92.
34. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, and Moss B: Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 2005;79:13454-13462.
35. Lustig S, Fogg C, Whitbeck JC, and Moss B: Synergistic neutralizing activities of antibodies to outer membrane proteins of the two infectious forms of vaccinia virus in the presence of complement. Virology 2004;328:30-35.
36. McDermott PF, Ciacci-Woolwine F, Snipes JA, and Mizel SB: High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect Immun 2000;68:5525-5529.
37. McDonald WF, Huleatt JW, Foellmer HG, et al.: A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J Infect Dis 2007;195: 1607-1617.
38. McEwen J, Levi R, Horwitz RJ, and Arnon R: Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella leads to partial protection in mice. Vaccine 1992;10:405-411.
39. Mizel SB, Graff A, Sriranganathan N, et al.: A fusion protein, flagellin=F1=V, is an effective plague vaccine in mice and two species of nonhuman primates. Clin Vaccine Immunol 2009;16:21-28.
40. Mizel SB, West AP, and Hantgan RR: Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J Biol Chem 2003;278: 23624-23629.
41. Tanaka S, Suzuki T, and Nishioka K: Assay of classical and alternative pathway activities of murine complement using antibody-sensitized rabbit erythrocytes. J Immunol Meth 1986;86:161-170.
42. Weimer ET, Ervin SE, Wozniak DJ, and Mizel SB: Immunization of young African green monkeys with OprF epitope8-OprI-type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 2009;27:6762-6769.
43. Weimer ET, Lu H, Kock N, Wozniak DJ, and Mizel SB: A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect Immun 2009;77: 2356-2366.
44. Wells J, Haidaris CG, Wright TW, and Gigliotti F: Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia. Infect Immun 2006;74:390-393.
45. West AP, Dancho BA, and Mizel SB: Gangliosides inhibit flagellin signaling in the absence of an effect on flagellin binding to toll-like receptor 5. J Biol Chem 2005;280:9482-9488.